Anti-IL-20 monoclonal antibodies have been evaluated as clinical candidates for the treatment and/or prevention of psoriasis, rheumatoid arthritis, atherosclerosis, osteoporosis, stroke and also bacterial lung infections [30]. This evidence concerns the gene IL20 and Stroke.